Overview

A Study to Evaluate the Effect of Pharmacokinetics (PK) of Acalabrutinib and Its Active Metabolite (ACP-5862) When Administered Alone and With Moderate CYP3A4 Inhibitors Fluconazole or Isavuconazole in Healthy Adult Participants

Status:
Completed
Trial end date:
2020-04-15
Target enrollment:
Participant gender:
Summary
This study will evaluate the effect of fluconazole and isavuconazole on the PK of acalabrutinib and its active metabolite, ACP-5862.
Phase:
Phase 1
Details
Lead Sponsor:
Acerta Pharma BV
Treatments:
Acalabrutinib
Fluconazole
Isavuconazole